KeyBank National Association’s Alnylam Pharmaceuticals ALNY Stock Holding History

KeyBank National Association’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$375K	Sell	1,246 -1,993	-62%	-$601K	﹤0.01%	1040
2026 Q1	$1.07M	Sell	3,239 -96	-3%	-$32.7K	﹤0.01%	583
2025 Q4	$1.33M	Sell	3,335 -725	-18%	-$321K	﹤0.01%	519
2025 Q3	$1.85M	Buy	4,060 +1,303	+47%	+$531K	0.01%	466
2025 Q2	$899K	Sell	2,757 -37	-1%	-$10.2K	﹤0.01%	599
2025 Q1	$754K	Sell	2,794 -68	-2%	-$17.5K	﹤0.01%	617
2024 Q4	$673K	Buy	+2,862	New	+$753K	﹤0.01%	672

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KeyBank National Association's ALNY Position: Q2 2026 in Review

KeyBank National Association reduced its Alnylam Pharmaceuticals (ALNY) stake by 62% in Q2 2026, selling an estimated $601K and leaving 1,246 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #1040.

KeyBank National Association first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.85M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

KeyBank National Association held 1,246 shares of Alnylam Pharmaceuticals worth $375K as of Q2 2026.
KeyBank National Association sold 1,993 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $601K.
Alnylam Pharmaceuticals made up ﹤0.01% of KeyBank National Association's portfolio in Q2 2026, its #1040 holding.
KeyBank National Association first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
KeyBank National Association's Alnylam Pharmaceuticals position peaked at $1.85M in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.